Predictions of Rising Potential for Bitcoin and Ethereum in 2020

A recent Forbes article provides insights into what could be building up for cryptocurrencies in the upcoming year. Clear indications are driven by the prospects of improved regulation for virtual asset service providers and the halving of Bitcoin. 

To begin with, Alexander Schell, Executive Director of the Crypto Valley Association, expects reports of the FATF to clarify understanding of how Virtual Asset Services Providers (VASP’s) operate and as a result help cryptocurrency adoption rates. To be specific, he believes that “Increased clarity from the FAFT on its position relating to VASPs globally will be particularly helpful… As the industry focuses on innovation and enterprise adoption, it is imperative that regulators do not implement a policy that will create obstacles and stifle the development of the industry.” 

To reiterate Alexander’s point, Nick Cowan, CEO of the Gibraltar Stock Exchange Group, equally weighs in on the importance of regulation in the future of digital currencies. On the basis thereof, the rising interest of Central banks and their adoption of blockchain technology could also ameliorate this growth. To quote, “We have also seen many Central Banks looking into the creation of their digital currencies and implementation of blockchain technology in their legacy financial ecosystems. 

Furthering this point is Florian Glatz, Co-founder of Fundament Securities as well as Benoit Coeure of Bank for International Settlements. The latter asserts the advantages of digital currencies and the building appetite amongst the central banks, specifically the European Central Banks (ECB) and their involvement in financial intermediation. Moreover, the expectations following the launch of the digital yuan by the People’s Bank of China will create speculation on digitizing the Euro. 

The price volatility surrounding digital assets in 2019 will see a decline. A un – optimistic Vaibhav Kadikar of CloseCross suggests that “In the new decade, the high volatility of the asset will become a distant memory. Price stabilization will spur a renewed interest from institutional investors to enter the space”.

Showing a slightly more doubting outlook is Dave Hodgson, Director of NEM Ventures. To quote accurately, “In 2019, we saw an increase in governments, regulators and central banks engaging with blockchain and crypto in general – sometimes positively and sometimes not so positively. Notably, the Financial Action Task Force (FATF) recommendations around Know Your Customer (KYC) continues to have an impact on how crypto exchanges operate; the Libra association continues to divide regulators, customers, and the crypto industry, and the launch of the first Security Tokens by both major institutions (Societe Generale) and national markets, such as Germany (BitBond), is making waves”. With that being said, he is still open to see where trends such as Bitcoin’s halving and the events following it will do to grab the public attention. 

The final points to consider are the releases of predominant technology upgrades by bigger chains, for example, ETH 2.0 and NEM with Catapult. With that considered, there remain hesitations on many of these factors following through with certainty and whether a stabilized year is ahead to come for the cryptocurrency market. 

Image via Shutterstock 

Think Tank Releases Report on the Blockchain-Based Genetic Data Network

Think Tank, dGen, releases a new report entitled, AI, Privacy, and Genomics: The Next Era of Drug Design”. It tackles the issue of privacy and access to genetic data for companies using AI to speed up and improve drug design.

Where the average drug today takes 10-12 years and cost $2 billion, Covid-19 forced this timeline to 12-18 months. Whether or not the cure will be delivered in the next six months remains unclear.

The bottom line is that more companies need access to more genetic data. We spoke with industry leaders from Aidence, Gero, Iktos, Alphanosos, e-Estonia, Qunatlib, Turbine, and more.

With a blockchain-based access network, our top predictions for 2030 are:

●   Better collaboration networks will emerge.

●   Genetic privacy laws will be overhauled.

●   AI will become a fundamental part of drug discovery.

●   Pharmaceutical giants won’t be toppled, but they won’t get out unscathed as biotech startups take the field.

Genetic information is central to many AI-enabled drug discovery startups. To expand this innovation, several issues with genetic data must first be resolved:

●   ownership

●   secure storage

●   availability to multiple research parties.

Ultimately, many privacy-preserving technologies leave the issue of ownership and auditing this system undisturbed. We propose a blockchain-based, decentralised pan-European biobank network to make information available to researchers, but log all access requests. This would also empower individuals to grant or deny these requests and track the use of their information.

Quotes:

Maxim Kholin, Gero Co-Founder

‘We believe that AI can accelerate the drug discovery process by proper understanding of human diseases from large biomedical data. The data-driven approach should help establish the genetic determinants and molecular markers of the disease’.

Pascal Mayer, Alphanosos Founder

‘While currently working really well on bacteria, we are confident [AI-enabled plant-based drug discovery] shall be successful in fighting viruses as well’.

‘Using edible plant extracts, like we do, in the development process of drugs, the risks of side effects are quite low[…] possibilities 10^10 or 10^30 [are available]. This is such a huge number that we use AI to quickly drive us through these possibilities’.

Tamás Török, Turbine Head of Business Development

‘Turbine is able to identify novel molecular targets to overcome the disease, and precisely select patients for whom the therapies will work best. Turbine’s Simulated Cell platform therefore generates novel biological knowledge through simulations rather than mining available biological data’.

Florian Marcus, e-Estonia Speaker

‘The patient will then see in the logbook, that this particular doctor looked at this particular patient dataset at this time for this and that reason. This can be challenged in court […] when the system was introduced, some doctors lost their licence over it’.

‘This logic of a rights-based access system is fundamental to the operation of e-Estonia, as is the notion of truth-by-design so I can always see who checked my data and hold them to account’.

Image source: dGen. Org

Exit mobile version